NANTES, France I October 30, 2018 I OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) presented at the World Immunotherapy Congress held on Oct. 29-31, 2018 in Basel, Switzerland. Bernard Vanhove, chief operating officer and director of R&D and international scientific collaborations, delivered a presentation titled, “Selective SIRP-alpha antibodies: next-generation checkpoint inhibitors of myeloid cells” during the session “Immunotherapy – Immune Checkpoint Inhibitors.”
The oral presentation featured selective SIRPα antagonist OSE-172, the company’s first-in-class myeloid checkpoint inhibitor that selectively targets the SIRPα receptor expressed on myeloid protumor suppressive cells.
The data resulting from human ex-vivo and preclinical studies mainly showed that antagonist of SIRPα
OSE-172:
- Led to dramatic changes in solid tumor microenvironment inducing significant increase of M1 inflammatory macrophages, activated T-cells and revealed higher dendritic cell and T-cell immune signatures with reduced sign of exhaustion;
- Led to the restoration of the chemoattracting capacity of macrophages resulting in T-cell migration from the periphery into the tumor nest, thereby converting ‘warm’ tumors into ‘hot’ tumors;
- Increased dendritic cell tumor-antigen specific presentation to T lymphocytes, leading to long-term anti-tumor memory immune responses;
- Prevented metastatic spread in aggressive cancer models;
- Preserved human T-cell functions due to the selective action of OSE-172 on SIRPα without binding to SIRPγ;
- Reduced tumor growth and increased survival significantly in various cancer models both in monotherapy and in combination with immune checkpoints inhibitors.
OSE-172 (BI765063) is a selective SIRPα antagonist antibody being developed under a global licence and collaboration agreement with Boehringer Ingelheim. The product is expected to enter clinical phase in Q1 2019, with potential application in various solid tumors.
ABOUT OSE Immunotherapeutics
OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmmune diseases. The company has a diversified first-in-class clinical portfolio consisting of several scientific and technological platforms including neoepitopes and agonist or antagonist monoclonal antibodies, all ideally positioned to fight cancer and autoimmune diseases. Our most advanced asset, Tedopi®, is a proprietary combination of 10 neo-epitopes aimed at stimulating T-lymphocytes and is currently in Phase 3 development in non-small cell lung cancer (NSCLC) after checkpoint inhibitor failure (anti PD-1 and anti PD-L1). In April 2018, Boehringer Ingelheim and OSE signed a global license and collaboration agreement to develop checkpoint inhibitor OSE-172 (anti-SIRPa monoclonal antibody) in multiple cancer indications. In July 2016, Janssen Biotech exercised a licensing option to continue clinical development of FR104 (an anti-CD28 mAb) in auto-immune diseases after positive Phase 1 results. In 2016, Servier Laboratories signed a two-step license option to develop OSE-127 (monoclonal antibody targeting the CD127 receptor, the alpha chain of the interleukin-7 receptor) to develop the product up to the completion of a Phase 2 clinical trial planned in autoimmune bowel disease and Sjogren’s syndrome.
SOURCE: OSE Immunotherapeutics
Post Views: 32
NANTES, France I October 30, 2018 I OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) presented at the World Immunotherapy Congress held on Oct. 29-31, 2018 in Basel, Switzerland. Bernard Vanhove, chief operating officer and director of R&D and international scientific collaborations, delivered a presentation titled, “Selective SIRP-alpha antibodies: next-generation checkpoint inhibitors of myeloid cells” during the session “Immunotherapy – Immune Checkpoint Inhibitors.”
The oral presentation featured selective SIRPα antagonist OSE-172, the company’s first-in-class myeloid checkpoint inhibitor that selectively targets the SIRPα receptor expressed on myeloid protumor suppressive cells.
The data resulting from human ex-vivo and preclinical studies mainly showed that antagonist of SIRPα
OSE-172:
- Led to dramatic changes in solid tumor microenvironment inducing significant increase of M1 inflammatory macrophages, activated T-cells and revealed higher dendritic cell and T-cell immune signatures with reduced sign of exhaustion;
- Led to the restoration of the chemoattracting capacity of macrophages resulting in T-cell migration from the periphery into the tumor nest, thereby converting ‘warm’ tumors into ‘hot’ tumors;
- Increased dendritic cell tumor-antigen specific presentation to T lymphocytes, leading to long-term anti-tumor memory immune responses;
- Prevented metastatic spread in aggressive cancer models;
- Preserved human T-cell functions due to the selective action of OSE-172 on SIRPα without binding to SIRPγ;
- Reduced tumor growth and increased survival significantly in various cancer models both in monotherapy and in combination with immune checkpoints inhibitors.
OSE-172 (BI765063) is a selective SIRPα antagonist antibody being developed under a global licence and collaboration agreement with Boehringer Ingelheim. The product is expected to enter clinical phase in Q1 2019, with potential application in various solid tumors.
ABOUT OSE Immunotherapeutics
OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmmune diseases. The company has a diversified first-in-class clinical portfolio consisting of several scientific and technological platforms including neoepitopes and agonist or antagonist monoclonal antibodies, all ideally positioned to fight cancer and autoimmune diseases. Our most advanced asset, Tedopi®, is a proprietary combination of 10 neo-epitopes aimed at stimulating T-lymphocytes and is currently in Phase 3 development in non-small cell lung cancer (NSCLC) after checkpoint inhibitor failure (anti PD-1 and anti PD-L1). In April 2018, Boehringer Ingelheim and OSE signed a global license and collaboration agreement to develop checkpoint inhibitor OSE-172 (anti-SIRPa monoclonal antibody) in multiple cancer indications. In July 2016, Janssen Biotech exercised a licensing option to continue clinical development of FR104 (an anti-CD28 mAb) in auto-immune diseases after positive Phase 1 results. In 2016, Servier Laboratories signed a two-step license option to develop OSE-127 (monoclonal antibody targeting the CD127 receptor, the alpha chain of the interleukin-7 receptor) to develop the product up to the completion of a Phase 2 clinical trial planned in autoimmune bowel disease and Sjogren’s syndrome.
SOURCE: OSE Immunotherapeutics
Post Views: 32
